🐋 RVMD ≈$4M Bullish Call Buy — Riding Post-ASCO Momentum in RAS Oncology

✅ RESOLVED — Next-Day OI Update (2026-06-10): $155C OI 114 → 5,091 (Δ +4,977 ≈ the 4,998 size). The bullish call buy opened fully as read.

Last updated: 2026-06-10

📅 June 9, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

A desk just put ≈$4M to work buying ≈4,998 RVMD July $155 calls — a confirmed fresh opening position in a name that just delivered one of the most striking Phase 3 oncology results in years. Revolution Medicines' daraxonrasib cut the risk of death in pancreatic cancer by 60% versus chemo at ASCO on May 31, sending the stock to an all-time high of $166.50 on June 1 before settling near $147. This is a momentum trade betting RVMD can recover toward $155 by July 17 on NDA-filing signals and continued post-ASCO re-rating — not a pre-data gamble.

---

📊 Company Overview

Revolution Medicines (NASDAQ: RVMD) is a clinical-stage precision-oncology company developing RAS(ON) inhibitors — drugs that target the active, cancer-driving form of mutant RAS:

• Market Cap: ≈$31.7 billion
• Sector: Biotechnology — clinical-stage precision oncology
• Lead Asset: Daraxonrasib (RMC-6236), an oral multi-selective RAS(ON) inhibitor for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
• Pipeline: Zoldonrasib (KRAS G12D-selective) and elironrasib (KRAS G12C-selective) round out the RAS(ON) platform
• Cash: ≈$4 billion post-April equity + convert raise — multi-year runway to a potential commercial launch

RVMD is pre-revenue, burning ≈$1.7–1.8B/year in R&D and operating costs, but the RASolute 302 Phase 3 result fundamentally changed the risk profile. It's no longer a binary bet on whether the science works — it's a regulatory and commercial execution story.

---

💰 The Option Flow Breakdown

📊 What Just Happened

At 12:19:45 ET on June 9, 2026, a desk executed a multi-leg auction — a facilitated price-improvement auction on the exchange — buying ≈4,998 RVMD July 2026 $155 calls at $7.85 across two prints for a total premium of ≈$4M. With spot at $146.76, the $155 strike sits ≈5.6% out of the money.

Full Trade Table 🤝 Multi-Leg Auction:

Total: ≈4,998 contracts | ≈$4M total premium | BTO (opening) | 🤝 Multi-Leg Auction

---

⏳ Come back tomorrow (≈06:30 ET pre-market) for the OI double-check. Today's prior OI was just 114 contracts — far below the ≈4,998 bought today — so we can largely confirm this is a fresh opening position (size ≫ OI means ≈4,884+ contracts had to be new opens). Still, the OPRA next-day OI snapshot is the definitive test: if OI rises to ≈4,998–5,100, it's confirmed fully open. If OI rises by less, a portion of the volume was pre-existing. Watch the June 10 pre-market OI for the final read.

---

🤓 What This Actually Means — Plain English

Let's break down what just happened in plain language:

Long OTM calls = a directional bullish bet. Buying the July $155 calls means this desk is paying $7.85 per contract (times 100 shares = $785 per contract, times ≈4,998 contracts = ≈$4M) for the right to buy RVMD at $155 on or before July 17, 2026. To profit, RVMD needs to climb from ≈$147 to above $162.85 by expiration (the $155 strike + $7.85 premium paid = breakeven). If RVMD stays below $155 at expiry, the entire ≈$4M is lost.

What is a multi-leg auction? This is not an urgent lit sweep — it's not someone panicking to buy before the market moves away. A multi-leg auction means the exchange ran a formal price-improvement auction: a broker submitted the order, competing market-makers bid against each other to fill it at the best possible price. The fill came in near the mid-price of the bid-ask spread (≈58% across the NBBO, a mild buy-lean). Translation: a desk negotiated a good fill on a large block through a structured process, with a known counterparty taking the other side. There's no identifiable significant paired option leg at this expiry, so the directional substance is straightforward long calls.

What is this trade NOT? It's not a pre-data gamble — Revolution Medicines already presented RASolute 302 at the ASCO Plenary on May 31. The pivotal readout is done. This trade is buying into the aftermath: post-ASCO momentum, NDA-filing signaling, and continued analyst re-rating. Think of it as a desk saying "yes, the big data dropped and the stock already spiked to $166.50 — but we think the re-rating isn't finished and the NDA news flow brings it back above $155 by mid-July."

Q2 earnings are just AFTER expiry (expected early-to-mid August). That's important — there's no fresh dated binary catalyst locked inside this trade's 38-day window. This isn't a binary earnings bet; it's a momentum and newsflow play.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

RVMD has had a remarkable year. The stock climbed into the RASolute 302 readout, then gapped to an all-time high of $166.50 on June 1 — one of the biggest single-session moves the name has seen — after the ASCO Plenary presentation and simultaneous NEJM publication confirmed a 60% reduction in risk of death versus chemotherapy in previously treated metastatic PDAC. Since then the stock has faded about 12% to the ≈$147–150 zone, which is a normal post-catalyst consolidation. The $155 call buyer is betting on a mean-reversion back toward the post-ASCO high zone.

Gamma-Based Support & Resistance Analysis

Current Price: ≈$150.3

The gamma exposure picture for RVMD right now is relatively simple — the name just went through a binary event and the positioning is still sparse:

🔵 Support Levels:

• $150.0 — Strong Support Wall. This is the dominant gamma level: a cluster of put gamma is concentrated right at $150, which means market-makers are hedging positions that effectively prop up the stock near this round number. As long as RVMD holds $150, the gamma structure is constructive.

🟠 Resistance Levels:

• The gamma resistance picture above current price is thin — there are no heavy call-gamma walls between ≈$150 and the $155 strike. That means there's less mechanical market-maker selling pressure capping the stock as it moves toward $155. For the call buyer, this is favorable: the path to breakeven isn't blocked by a wall of dealer hedging.

What this means for the trade: The $150 gamma floor is meaningful short-term support. A break below $150 with conviction would be a warning sign for the July $155 call position. Holding $150 and drifting higher — especially on NDA-related newsflow — is the scenario the call buyer needs.

Implied Move Analysis

Options market pricing for upcoming expirations (from ≈$150.27):

• 📅 Weekly (June 18 — 9 days): ±$9.47 (±6.3%) → Range: $140.80 – $159.74
• 📅 Monthly OPEX (July 17 — 38 days — THIS TRADE!): ±$31.02 (±20.64%) → Range: $119.25 – $181.29
• 📅 Quarterly Triple Witch (September 18 — 101 days): ±$47.44 (±31.57%) → Range: $102.83 – $197.71
• 📅 LEAP (January 2028 — 591 days): ±$104.76 (±69.71%) → Range: $45.51 – $255.03

Translation for regular folks: For the July 17 expiration — the one this ≈$4M trade is riding — the market is pricing in a ±20.6% move from current levels over the next 38 days. That puts the upper end of the implied range at ≈$181.29, well above the $155 strike. In plain terms: the options market thinks RVMD reaching $155 by July 17 is quite plausible. The $162.85 breakeven sits comfortably inside the upper half of that implied range. This trade is not as far out of the money as it might look at first glance.

---

🎪 Catalysts

✅ Already Happened — The Dominant Catalyst

RASolute 302 Phase 3 Readout — ASCO Plenary, May 31, 2026

This is the headline. Revolution Medicines presented RASolute 302 data in the ASCO Plenary session and simultaneously published in the New England Journal of Medicine. The results were striking: daraxonrasib delivered a median overall survival of 13.2 months versus 6.6–6.7 months for chemotherapy in previously treated metastatic PDAC — a hazard ratio of 0.40, cutting the risk of death by 60%. Progression-free survival also roughly doubled versus chemotherapy. The NEJM publication at the same time amplified KOL endorsement and the "new standard of care" narrative.

The stock spiked to an all-time high of $166.50 on June 1, then faded to ≈$147. The catalyst is behind us — but the re-rating process is not finished.

🔥 Active Catalysts Before July 17 (Inside This Trade's Window)

NDA Filing Signaling — Daraxonrasib U.S. NDA targeted 2H 2026

This is the option-relevant catalyst that keeps the $155 strike alive. Management targets a U.S. NDA submission in 2H 2026 under the FDA Commissioner's National Priority Voucher program. Any conference appearance or press release where management signals the NDA filing has begun — or accelerated — would be a direct upside trigger within the July window. The FDA already granted Breakthrough Therapy and Orphan Drug designations, and an Expanded Access Program is live for pretreated PDAC patients.

Post-ASCO Analyst Re-Rating — Sell-Side Still Catching Up

The readout is only days old and the Street is still revising. RBC Capital raised its price target to $182 on June 2, and Oppenheimer moved to $195 on June 1. With a consensus target now skewing around $186, additional Street upgrades (or new initiations) could provide incremental upside pressure through June and early July.

Second Pipeline Pillar — Zoldonrasib NSCLC Progress

Zoldonrasib (RMC-9805) holds FDA Breakthrough Therapy Designation for KRAS G12D-mutated NSCLC (granted January 8, 2026). Updated Phase 1 data at AACR 2026 showed a confirmed ORR of 52% and median PFS of 11.1 months in checkpoint/platinum-pretreated NSCLC — making this a real second asset. Any incremental NSCLC data updates at summer conferences add to the mosaic.

⚠️ Key Risk: Q2 Earnings Land Just AFTER Expiry

Q2 2026 earnings are expected in early-to-mid August 2026 — just after July 17. This means the July $155 call buyer does NOT get the benefit of a Q2 earnings catalyst. Earnings would be the next clean newsflow event for the stock, but it falls outside the trade's life. If nothing materially moves RVMD before July 17, the calls expire worthless.

---

🎲 Price Targets & Scenarios Through July 17

📈 Bull Case — RVMD reclaims $155+

What gets it there:

• 🚀 NDA submission announcement or management signal at a June/July investor conference triggers a gap back toward the post-ASCO high zone
• 📈 Additional analyst upgrades and new initiations (several buy-side shops still updating models)
• ✅ Sustained KOL and medical-community momentum as the "new standard of care" narrative sets in via NEJM citations and tumor-board presentations
• 📊 The ±20.6% July implied range puts $181 as the top of the market's own pricing — $155 is fully inside it

Trade economics: July $155 call at $7.85 breakeven = $162.85. At spot $170 on July 17, each contract is worth ≈$15 (≈91% gain). The ≈4,998 contracts would be worth ≈$7.5M on ≈$4M invested.

🎯 Base Case — RVMD churns between $145–155

What this looks like:

• Post-catalyst consolidation drags on; no fresh NDA signaling before expiry
• Stock trades the $150 gamma floor and the $155–160 technical ceiling, oscillating without conviction
• The July $155 calls decay as theta erodes premium day by day; a final-week rally attempt may or may not materialize

Trade economics: The calls expire worthless or nearly so. Total loss ≈$4M.

📉 Bear Case — RVMD slips below $145

What goes wrong:

• Broader biotech or market selloff drags the stock lower
• Concern about NDA timeline slippage on the National Priority Voucher pathway (novel, unproven on timelines)
• "Sell the news" pressure lingers longer than expected; the May 31 catalyst is fully in the price
• A dilution overhang reminder (≈$2.1B April equity + convert raise still fresh)

Trade economics: Deep OTM calls accelerate their decay. At spot $140 by mid-July, the $155 calls are likely worth pennies. Loss on the position approaches 90–100%.

---

💡 Trading Ideas for 4 Types of Traders

🚀 YOLO Trader

The ≈$4M desk position is already the aggressive version. If you want to ride alongside it on a smaller scale, buying a handful of RVMD July 17 $155 calls at ≈$7.85 gives you asymmetric exposure: max loss is what you paid, and the ±20.6% July implied range puts $162–181 within the market's own pricing. But remember — with 38 days to go and no confirmed catalyst inside the window, theta decay is real and the breakeven is $162.85. This is a bet on momentum, not a sure thing.

📈 Swing Trader

Rather than buying the OTM call outright (expensive on a biotech), consider a July call spread: buy the $155 call and sell the $165 or $170 call to partially offset the cost. You'd cap your upside at $165/170, but you'd reduce your breakeven meaningfully and lower the capital at risk. If the NDA-signaling thesis plays out, a $155/$165 spread profits handsomely with less premium at stake than buying the $155 outright.

🛡️ Premium Collector

This trade is structurally positioned against you — whoever sold these calls to the auction is either a market-maker delta-hedging or someone willing to be short volatility in a post-binary name. If you're already long RVMD stock and want to generate income, selling covered calls at $160–165 against your shares captures some of the elevated IV while giving the stock room to run to the recent all-time high zone before getting called away. Just know that if NDA news drops and RVMD gaps back to $170+, you'd be capped out.

🌱 Beginner / Entry-Level

Here's the plain version: someone just paid ≈$4M for the right to buy RVMD at $155 a share by July 17. They think the stock — which briefly traded at $166.50 last week — can get back there. They're not betting on new clinical data (that already came out); they're betting on the momentum of good news and the company filing for FDA approval. The risk is that the stock stalls, their options expire worthless, and they lose the entire ≈$4M. Never risk more than you can afford to lose entirely on trades like this. If you're curious about the stock itself, watching whether RVMD can reclaim $155 in the next five weeks is a good learning exercise in post-catalyst dynamics.

---

⚠️ Honest Risk Factors & Limits of the Tape

What we know for certain from the OPRA tape:

• ✅ ≈4,998 July $155 calls were bought at $7.85 in a multi-leg auction at 12:19:45 ET on June 9
• ✅ Prior OI was 114 — this was overwhelmingly a fresh opening position
• ✅ The fill was near mid-price (≈58% across NBBO), consistent with a facilitated auction, not a panic sweep

What the tape cannot tell us:

• ❌ Who the buyer is — broker, institution, fund, individual
• ❌ Whether this is a standalone directional bet or part of a larger portfolio hedge (e.g., paired against a short position elsewhere)
• ❌ Who took the other side of the auction
• ❌ The buyer's exact cost basis or broader portfolio context

The critical risk unique to this setup — the binary is behind us:

The RASolute 302 data already printed May 31. The stock already spiked to $166.50 and faded. A significant portion of the post-trial re-rating has happened. The $155 call buyer needs the stock to RISE ≈11% from ≈$147 to reach their break-even of $162.85 by July 17 — and there is no confirmed dated catalyst inside that window. The NDA filing is only guided to "2H 2026" — it could be August, September, or October. Q2 earnings land after expiry. This trade lives or dies on NDA-signaling newsflow and continued sell-side momentum, not a fresh data readout.

The valuation reality: RVMD carries a ≈$31.7 billion market cap on zero product revenue, a Q1 net loss of $453.8M, and an FY2026 operating expense guide of $1.7–1.8B. Even with a generational Phase 3 result, any FDA review delay or label restriction would pressure a stock that has priced in much of the RASolute 302 success. The ≈$4B cash position removes near-term financing risk, but the stock's multibillion-dollar valuation demands execution on the NDA and a commercial launch that hasn't started yet.

Multi-leg auction ≠ aggressive urgency. This trade was facilitated through a structured auction, not a frantic lit sweep. A known counterparty took the other side. That does not invalidate the bullish thesis, but it means the print reflects a desk taking a measured position — not someone with urgent information scrambling to buy before a move.

---

🎯 The Bottom Line

Here's the deal: A desk paid ≈$4M to open ≈4,998 RVMD July $155 calls in a negotiated multi-leg auction — a confirmed fresh position in a name that just delivered the best Phase 3 pancreatic cancer data anyone has ever seen. The bet is that RVMD's post-ASCO momentum, NDA filing signals, and sell-side re-rating push the stock back above $155 over the next 38 days.

It's a credible trade — the implied volatility market already prices a ±20.6% move through July 17, and $155 sits comfortably inside that range. The $150 gamma support wall provides a near-term floor.

But be eyes-wide-open about what makes this hard: the dominant catalyst is in the rearview mirror, there's no fresh confirmed binary event before expiry, Q2 earnings land just after July 17, and the breakeven at $162.85 requires an ≈11% rally from today. The entire $4M is at risk if RVMD stays quiet into mid-July.

Watch the two signals that matter: any NDA submission announcement or conference management commentary, and whether RVMD holds and builds from the $150 gamma floor. If the stock can't reclaim $155 on its own before late June, the clock gets uncomfortable for the July calls.

📅 Key date to watch: July 17, 2026 — expiration of these calls. Any NDA filing signal or analyst catalyst before then is the catalyst pathway.

---

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational and informational purposes only and is not financial advice. Past performance does not guarantee future results. A trade of ≈4,998 contracts represents institutional-scale positioning that most retail traders should not replicate dollar-for-dollar. Always size positions to what you can afford to lose entirely, and consider consulting a licensed financial advisor before trading. The opening status described here is based on prior-day OI of 114 versus same-day volume — the OPRA next-day OI snapshot (≈06:30 ET on June 10) is the definitive confirmation.